Now with another 150 million, Rapport is extremely well positioned to advance our ongoing clinical programs in seizure and psychiatric disorders and to expand our pipeline by harnessing our unique capability to leverage receptorassociated proteins for precision neuromedicine Ceesay said in a statement Wednesday